检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial

Anwen Xiong,Shengxiang Ren,Huaimin Liu,Liyun Miao,Lei Wang,Jianhua Chen,Wei Li,Runpu Li,Xiang Wang,Zhiwei Lu,Donglin Wang,Xiaohong Wu,Zhihua Liu,Ligang Xing,Yimin Mao,Chunling Liu,Aiping Zeng,Hongrui Niu,Yingying Du,Yuping Sun,Yueyin Pan,Yanping Hu,Xiaodong Zhang,Xueqin Chen,Zhiyong Ma,Na Li,Jianyong Zhang,Min Zhao,Xiaoling Li,Feng Ye,Mingjun Li,Guohua Yu,Xiaomeng Zhang,Jie Min, Dong Han,Jin Li,Caicun Zhou

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer（2022）

引用 8|浏览18
暂无评分
摘要
SH-1028 is efficacious and tolerable in second-line treatment of patients with advanced NSCLC with positive EGFR T790M.
更多
查看译文
关键词
SH-1028,EGFR T790M mutation,Efficacy,Safety
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要